Faron reports median overall survival not reached in BEXMAB trial for frontline higher-risk MDS patients without TP53 mutations

• Faron Pharmaceuticals reported an initial overall-survival readout from the Phase 1/2 BEXMAB trial in frontline higher-risk MDS.
• Survival appeared most encouraging in patients without TP53 mutations or with monoallelic TP53 mutations, with outcomes still developing.
• Patients with biallelic TP53 mutations showed survival broadly consistent with prior experience in this aggressive subgroup.
• Detailed results will be presented at a scientific meeting later in 2026 as follow-up continues.
• Data support preparations for BEXERA, a planned randomized study of bexmarilimab with azacitidine in frontline higher-risk MDS.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Faron Pharmaceuticals Oyj published the original content used to generate this news brief on July 27, 2026, and is solely responsible for the information contained therein.